Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
This study is ongoing, but not recruiting new patients.
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma
Condition: Cutaneous T-Cell Lymphoma
Phase: Phase 3
External Link: https://clinicaltrials.gov/show/NCT01728805